BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 28919620)

  • 41. Method evaluation of pepsinogen I/II assay based on chemiluminescent immunoassays and comparison with other test methods.
    Cho EJ; Kim HK; Jeong TD; Ko DH; Bae SE; Lee JS; Lee W; Choe JW; Chun S; Jung HY; Min WK
    Clin Chim Acta; 2016 Jan; 452():149-54. PubMed ID: 26585753
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Serum pepsinogen and gastric cancer screening.
    Mukoubayashi C; Yanaoka K; Ohata H; Arii K; Tamai H; Oka M; Ichinose M
    Intern Med; 2007; 46(6):261-6. PubMed ID: 17379991
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cancer high-risk subjects identified by serum pepsinogen tests: outcomes after 10-year follow-up in asymptomatic middle-aged males.
    Yanaoka K; Oka M; Mukoubayashi C; Yoshimura N; Enomoto S; Iguchi M; Magari H; Utsunomiya H; Tamai H; Arii K; Ohata H; Fujishiro M; Takeshita T; Mohara O; Ichinose M
    Cancer Epidemiol Biomarkers Prev; 2008 Apr; 17(4):838-45. PubMed ID: 18398025
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Only serum pepsinogen I and pepsinogen I/II ratio are specific and sensitive biomarkers for screening of gastric cancer.
    Mansour-Ghanaei F; Joukar F; Baghaee M; Sepehrimanesh M; Hojati A
    Biomol Concepts; 2019 May; 10(1):82-90. PubMed ID: 31188744
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cutoff Pepsinogen Level for Predicting Unintendedly Eradicated Cases of Helicobacter pylori Infection in Subjects with Seemingly Normal Pepsinogen Levels.
    Kishikawa H; Kimura K; Ito A; Arahata K; Takarabe S; Kaida S; Miyauchi J; Miura S; Kanai T; Nishida J
    Digestion; 2017; 95(3):229-236. PubMed ID: 28355604
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The correlation between histological gastritis staging- 'OLGA/OLGIM' and serum pepsinogen test in assessment of gastric atrophy/intestinal metaplasia in China.
    Wang X; Lu B; Meng L; Fan Y; Zhang S; Li M
    Scand J Gastroenterol; 2017 Aug; 52(8):822-827. PubMed ID: 28436254
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term outcome of group D patients with negative serum anti-Helicobacter pylori antibody and positive serum pepsinogen test in healthy Koreans.
    Han YM; Chung SJ; Choi JM; Lee C; Kim JS
    J Dig Dis; 2018 Sep; 19(9):529-539. PubMed ID: 30117281
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Label-free detection of pepsinogen 1 and 2 by polyethylene coating Lamb microfluidic device.
    Wei W; Zhang W; Li C; Kong H; Guo Z; Zhang Z; Bastien F; Gong Y; Wang H; Zhou L
    Biosens Bioelectron; 2019 Mar; 129():231-237. PubMed ID: 30287174
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Pepsinogen I, pepsinogen II, and pepsinogen I/II ratio].
    Miki K; Sasajima M; Ohtsuka T; Urita Y
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():741-3. PubMed ID: 16149628
    [No Abstract]   [Full Text] [Related]  

  • 50. Relationship between Helicobacter pylori status and serum pepsinogens as serologic markers in atrophic gastritis.
    Bölükbaş C; Bölükbaş FF; Ovünç O; Kiliç G; Dalay R; Güven H; Uras F; Yardimci TK; Sökmen MH; Agan AF; Pişkinpaşa N
    Turk J Gastroenterol; 2006 Sep; 17(3):172-6. PubMed ID: 16941249
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gastric Cancer Screening by Combined Assay for Serum Anti-Helicobacter pylori IgG Antibody and Serum Pepsinogen Levels--The ABC Method.
    Yamaguchi Y; Nagata Y; Hiratsuka R; Kawase Y; Tominaga T; Takeuchi S; Sakagami S; Ishida S
    Digestion; 2016; 93(1):13-8. PubMed ID: 26789514
    [TBL] [